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ABSTRACT

A

cute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation.
While improvements in treatment and supportive care have
occurred, it is unknown whether these advances have resulted in
haematologica | 2017; 102(5)
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improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period,
and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum
overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute
myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%)
received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for
2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 19992001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-versus-host
disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and
37% for 1999-2001, 2002-2005, and 2006-2012, respectively (P<0.001). Considering the total study population, univariate analysis demonstrated significant improvements in overall survival and treatmentrelated mortality over time, and deaths from organ failure and infection declined. On multivariate analysis, significant improvements in overall survival (P=0.003) and treatment-related mortality (P=0.008)
were only noted among those originally treated with tacrolimus-based graft-versus-host disease prophylaxis, and these effects were most apparent among those with overall grade II acute graft-versus-host disease. In conclusion, survival has improved over time for tacrolimus-treated transplant recipients with
acute graft-versus-host disease.

Introduction

Methods

Graft-versus-host disease (GvHD) remains one of the
most significant barriers to the success of allogeneic
hematopoietic stem cell transplantation (HCT). Current
pharmacological approaches fail to prevent acute GvHD
completely.1-3 Furthermore, durable resolution of acute
GvHD following primary steroid-based therapy is infrequent,4-6 and long-term success of systemic immunosuppressive therapies given after steroid therapy is elusive.7
Consequently, acute GvHD and its allied infectious complications and organ failure contribute greatly to early
mortality after HCT. However, advances in supportive
care over time, in particular improvements in the coverage and potency of antimicrobial agents (e.g. antibacterial, antiviral, and antifungal drugs), hold promise to
improve survival for those patients affected by acute
GvHD.
Previous large analyses have demonstrated improvement in survival outcome over time for HCT recipients,
despite evolution in overall practices including increasing
HCT recipient age, use of unrelated donors, and peripheral blood stem cells as the predominant graft type.8 More
recent transplants have been shown to have improved
overall mortality, as well as reducing grade III-IV acute
GvHD, major organ injury, and life-threatening infections
through the early post-HCT period.9 Further insight is
needed, however, as studies have not examined change in
survival outcome over time exclusively in an acute
GvHD-affected population, survival outcome according
to maximal acute GvHD grade, or effects according to
specific GvHD prophylaxis. Additionally, the studies
have not examined outcomes of HCT procedures conducted after 2007.
Accordingly, we conducted a large registry analysis to
determine whether survival outcome after a diagnosis of
acute GvHD has improved significantly over time.

Data source
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The Center for International Blood and Marrow Transplant
Research (CIBMTR) is a voluntary working group of more than
450 transplant centers worldwide that contribute detailed data
on consecutive allogeneic HCT to the Statistical Center at the
Medical College of Wisconsin in Milwaukee or the National
Marrow Donor Program (NMDP) Coordinating Center in
Minneapolis. Approximately two-thirds of all active transplantation centers worldwide report data to the registry. The registry
database includes information on 40-45% of all patients who
have received an allotransplant since 1970, with annual updates.
Compliance is assessed by periodic audits and accuracy of data
is ensured by computerized record checks, physician review of
submitted data and on-site audits. Observational studies conducted by the CIBMTR are done with a waiver of informed consent and in compliance with Health Insurance Portability and
Accountability Act regulations as determined by the
Institutional Review Board and Privacy Officer of the Medical
College of Wisconsin.

Selection of patients and definitions
The CIBMTR population of patients consisted of first postmyeloablative sibling or unrelated donor, blood or marrow allogeneic HCT recipients with acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndromes transplanted
between 1999 and 2012 who developed grade II-IV acute GvHD
within 100 days after HCT. Only those with acute GvHD onset
within 100 days after HCT were included, as this analysis is
focused on classic acute GvHD, not late acute GvHD. The maximal severity of acute GvHD for each subject was used in all
analyses.10 A total of 2,905 eligible cases with complete research
data available were identified. This final study population was
generated from the total (n=17,244) number of first US allogeneic HCT procedures for acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes from 1999959
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2012 after exclusion of umbilical cord blood transplants
(n=2,748), donor types other than matched sibling or unrelated
donors (n=654), in-vivo or ex-vivo T-cell-depleted grafts (n=4,149),
reduced intensity or non-myeloablative conditioning regimens
(n=2,133), those with grade 0-1 acute GvHD or missing GvHD
information (n=4,002), those surviving patients with <100 days
follow up (n=18), relapse prior to acute GvHD diagnosis
(n=176), development of acute GvHD more than 100 days after
HCT (n=88) or within 7 days of HCT (n=113), or other consent
or research form related exclusions (n=258). Overall, molecular
typing was available for 1,810 cases (83%) with >99.9% concordance between the 8/8 and well-matched and ≤7/8 and partially
or mismatched groups.

Study endpoints
The primary endpoint was overall survival (OS), defined as
death from any cause. Secondary endpoints considered were the
following: disease-free survival (DFS), defined as survival in continuous complete remission; transplant-related mortality (TRM),
defined as death in continued remission; malignancy relapse,
defined as recurrence of the malignancy for which HCT was performed; and chronic GvHD.11 All endpoints were estimated from
the date of acute GvHD onset, as the exact date of maximal
grade II-IV acute GvHD was not collected.

Statistical analysis
Included patients were divided into three cohorts based on the
year of transplant (1999-2001, 2002-2005, 2006-2012).
Univariate analysis compared the outcomes of OS, DFS, TRM,
relapse and chronic GvHD incidence between these three
cohorts. Multivariate analyses were performed using Cox proportional hazards regression models. All the clinical variables
were tested for the affirmation of the proportional hazards
assumption. Factors violating the proportional hazards assumption were adjusted through stratification. A stepwise model
selection procedure was then used to identify clinical variables
that were associated with each particular outcome with a
threshold of 0.05 for both entry and stay in the model.
Interactions between the main variable ‘Year of transplant’ and
the adjusted covariates were tested, and no significant interactions between the ‘Year of transplant’ and the adjusted covariates were detected at the significance level of 0.01 in any of the
models. A significant center effect was detected for the outcomes of OS and TRM for patients with grade II-IV acute GvHD
only among those treated with cyclosporine A, and adjustment
for this effect was performed. Potential covariates included
patient’s age (by decades), sex and race (Caucasian, African
American, Other), Karnofsky performance status (<90%, ≥90%),
time from diagnosis to HCT (<2 weeks, 2 weeks – 1 month, 2

Table 1. Transplantation (patient, donor, and transplant) and graft-versus-host disease characteristics.

Age, median (range), years
Male sex, n (%)
Race Caucasian, n (%)
Karnofsky score > 90% at transplant, n (%)
Diagnosis, n (%)
Acute myeloid leukemia
Acute lymphoblastic leukemia
Myelodysplastic syndromes
Disease status at transplant*, n (%)
Early
Intermediate
Advanced
Unknown
HLA-identical sibling donor age, years, median (range)
Unrelated donor age, years, median (range)
Donor/recipient sex match, n (%)
Female/male
Other
Donor/recipient CMV status, n (%)
+/+
+/-/+
-/Missing
Donor/recipient HLA match**, n (%)
HLA-identical sibling
URD well-matched
URD partially matched
URD mismatched
URD missing
Time from diagnosis to transplant, months, median (range)

1999-2001 (n=497)

Year of transplant
2002-2005 (n=962)

2006-2012 (n=1446)

P-Value

34 (1 - 63)
284 (57)
429 (86)
320 (64)

37 (<1 - 67)
583 (61)
799 (83)
609 (63)

43 (<1 - 70)
805 (56)
1174 (81)
915 (63)

<0.001
0.06
0.05
<0.001
<0.001

257 (52)
167 (34)
73 (15)

502 (52)
343 (36)
117 (12)

879 (61)
364 (25)
203 (14)

166 (33)
158 (32)
173 (35)
0
40 (<1 - 67)
35 (19 - 59)

417 (43)
272 (28)
267 (28)
6 (<1)
43 (1 - 71)
35 (18 - 59)

766 (53)
298 (21)
370 (26)
12 (<1)
47 (2 - 75)
33 (18 - 61)

103 (21)
393 (79)

209 (22)
753 (78)

285 (20)
1160 (80)

91 (18)
61 (12)
129 (26)
194 (39)
22 (4 )

232 (24)
99 (10)
310 (32)
296 (31)
25 (3 )

386 (27)
177 (12)
435 (30)
415 (29)
33 (2 )

107 (22)
171 (34)
149 (30)
70 (14)
0
9 (<1 - 238)

166 (17)
497 (52)
221 (23)
77 (8)
1 (<1)
7 (<1 - 197)

424 (29)
764 (53)
207 (14)
25 (2)
26 (2 )
6 (<1 - 279)

<0.001

0.001
<0.001
0.50

<0.001

<0.001

<0.001
continued on the next page
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months – 100 days), disease (acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes), disease status at time of HCT (early, intermediate, advanced), donor type
and age (HLA-identical sibling, unrelated well-matched 18-32
years, unrelated well-matched 33-49 years, unrelated wellmatched 50+ years, unrelated partially or mismatched 18-32
years, unrelated partially or mismatched 33-49 years, unrelated
partially or mismatched 50+ years),12 donor-recipient sex match,
donor-recipient cytomegalovirus serological status, use of total
body irradiation (TBI) in the regimen, graft source (bone marrow, peripheral blood mobilized stem cells), and GvHD prophylaxis (cyclosporine ± others, and tacrolimus ± others). The product limit estimator proposed by Kaplan Meier was used to estimate the median and range of the follow-up time. The probabilities of OS and DFS for all patients were calculated using the
Kaplan Meier estimator, with the variance estimated by the
Greenwood formula. Cumulative incidence estimates were calculated for other endpoints to account for competing risks.
Non-relapse death was a competing risk in the estimation of
malignancy relapse, death without chronic GvHD was a competing risk for estimation of chronic GvHD, and relapse was a
competing risk for estimation of TRM. SAS version 9.4 (SAS
Institute, Cary, NC, USA) was used for all the analyses.

Results
Patients
Between 1999 and 2012, 2,905 un-manipulated blood
(66%) or marrow (34%) sibling (24%) or unrelated donor
(76%) allograft recipients with acute myeloid leukemia
(56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) developed grade II-IV acute
GvHD. Conditioning was myeloablative in all cases.
Among the 1,759 patients who received TBI-based conditioning, 1326 (75%) received cyclophosphamide/TBI, 210
(12%) received cyclophosphamide/TBI/others, and 153
(9%) received TBI/etoposide. Among the 1,146 patients
who did not receive TBI as a part of their conditioning
regimen, 691 (60%) received busulfan/cyclophosphamide, 114 (10%) received busulfan/cyclophosphamide/others, and 295 (26%) received busulfan/fludarabine as their regimen. Donor, recipient, and transplant characteristics are summarized in Table 1. The
median follow-up for surviving patients was 144 (4-174),
97 (4-147) and 60 (8-99) months for those transplanted in
1999-2001, 2002-2005, and 2006-2012, respectively. Of
the 1,077 patients who received cyclosporine-based

continued from the previous page

TBI-based conditioning regimen, n (%)
Marrow graft, n (%)
Blood graft, n (%)
GvHD prophylaxis, n (%)
Cyclosporine-based
Tacrolimus-based
Acute GvHD grade
II
III
IV
Acute GvHD-effected organs
Skin + Gut + Liver
Skin + Gut
Skin + Liver
Gut + Liver
Skin only
Gut only
Liver only
Acute GvHD treatment, n (%)
Steroids + ATG + others
Steroids + MAB + others
Steroids only
Missing
Time from transplant to acute GvHD grade II-IV onset,
days, median (range)
< 2 weeks, n (%)
2-4 weeks, n (%)
1-2 months, n (%)
2 months – 100 days, n (%)
Follow-up of survivors, months, median (range)

371 (75)
313 (63)
184 (37)

640 (67)
346 (36)
616 (64)

748 (52)
329 (23)
1117 (77)

359 (72)
132 (27)

473 (49)
472 (49)

245 (17)
1163 (80)

219 (44)
190 (38)
88 (18)

507 (53)
310 (32)
145 (15)

904 (63)
368 (25)
174 (12)

133 (27)
125 (25)
70 (14)
21 (4 )
85 (17)
56 (11)
7 (1 )

189 (20)
289 (30)
72 (7)
42 (4 )
201 (21)
153 (16)
16 (2 )

193 (13)
562 (39)
63 (4 )
42 (3 )
224 (15)
345 (24)
17 (1 )

47 (9 )
51 (10)
380 (76)
19 (4 )
23 (8-94)

53 (6)
133 (14)
739 (77)
37(4 )
24 (8-100)

43 (3 )
159 (11)
1172 (81)
72 (5 )
26 (7-100)

123 (25)
221 (44)
128 (26)
25 (5 )
144 (4-174)

238 (25)
416 (43)
255 (27)
53 (6 )
97 (4-147)

259 (18)
647 (45)
407 (28)
133 (9 )
60 (8-99)

<0.001
<0.001
<0.001

<0.001

<0.001

<0.001

<0.001

CMV: cytomegalovirus; HLA: human leukocyte antigen; URD: unrelated; TBI: total body irradiation; ATG: antithymocyte globulin; MAB: monoclonal antibodies. *Disease status is
categorized as follows: Early: acute myeloid leukemia/acute lymphoblastic leukemia (first complete remission); myelodysplastic syndromes (refractory anemia, refractory anemia with ringed sideroblasts/pre-HCT marrow blasts <5%); Intermediate: acute myeloid leukemia/acute lymphoblastic leukemia (second complete remission or beyond);
Advanced: acute myeloid leukemia/acute lymphoblastic leukemia (relapse/primary induction failure) myelodysplastic syndromes (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia or marrow blasts ≥5%). **Donor-recipient matching definitions as previously defined by
Weisdorf, et al. 2008.12
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GvHD prophylaxis, 922 (86%) also received methotrexate while 56 (5%) received mycophenolate mofetil
(MMF); 28 of these received both methotrexate and
mycophenolate mofetil. The remainder mostly received
cyclosporine alone ± steroids (n=87, or 8%). Of the 1,767
patients who received tacrolimus-based GvHD prophylaxis, 1,376 (78%) also received methotrexate while 229
(13%) received mycophenolate mofetil; 63 of these
received both methotrexate and mycophenolate mofetil.
The remainder mostly received tacrolimus with sirolimus
(n=99, or 6%). Other infrequent approaches were seen in
both groups, in the order of <1-2% of the total each.
Trends in GvHD prophylaxis, in this patient population
that developed acute GvHD, favored predominant use of
tacrolimus-based approaches in the later time period.
When compared to cyclosporine-based GvHD prophylaxis, recipients of tacrolimus-based GvHD prophylaxis
were comparable, but were more likely to have had a
well-matched unrelated donor across all time periods
(P<0.001), and to have received peripheral blood stem
cells in recent years (P<0.001) (data not shown).

Characteristics of the acute graft-versus-host disease
Overall, the proportion of grade III-IV acute GvHD
decreased over time, being 56%, 47%, and 37% for the

periods 1999-2001, 2002-2005, and 2006-2012, respectively (P<0.001). Time of onset of acute GvHD remained
unchanged over time. The proportion of patients with
skin, gut and liver (concurrent 3-organ involvement) acute
GvHD decreased (P=0.0014), while gut acute GvHD with
or without skin involvement increased with time
(P<0.0001 and P<0.0001, respectively). The majority of
patients in all time cohorts were treated with steroids
only as primary acute GvHD therapy. Approximately 1520% received antithymocyte globulin or other monoclonal antibodies in addition to corticosteroids (Table 1).

Outcomes
Univariate analyses summarized in Table 2 showed
improvements in OS as well as a reduction in TRM at 100
days, 6 months, and 1, 2, and 3 years for patients who
developed grade II or grade III-IV acute GvHD.
Proportionally, relapse of the primary disease,
GvHD/infection and organ failure were the causes of the
majority of deaths overall; however, trends over time supported reductions in idiopathic pneumonia, organ failure,
hemorrhage, and infectious mortality (Table 3). No significant differences in relapse or chronic GvHD were
observed across time period cohorts for those with overall maximal grade II acute GvHD. Alongside a marked

Table 2. Univariate probabilities of transplant outcomes, among allogeneic transplant recipients who developed acute graft-versus-host disease grade
II or grade III-IV.

Outcomes

N. evaluated

Acute GvHD grade II
Overall survival
100-day
6-month
1-year
2-year
3-year
Relapse
100-day
6-month
1-year
2-year
3-year
Transplant-related mortality
100-day
6-month
1-year
2-year
3-year
Disease-free survival
100-day
6-month
1-year
2-year
3-year
Chronic GvHD
100-day
6-month
1-year
2-year
3-year

1999-2001
Probability (95%CI)

219

2002-2005
N. evaluated Probability (95%CI)
507

85 (80-90)%
74 (68-79)%
58 (51-65)%
46 (39-52)%
41 (34-47)%
214

502

875

502

214

875

502

4 (3-6)%
7 (6-9)%
12 (10-14)%
17 (15-20)%
20 (17-23)%
875

80 (76-83)%
67 (63-71)%
55 (50-59)%
45 (41-50)%
43 (38-47)%
498

31 (25-37)%
44 (37-50)%
55 (48-61)%
56 (50-63)%
57 (50-63)%

14 (12-16)%
22 (20-25)%
28 (25-31)%
32 (29-35)%
35 (32-38)%

7 (5-10)%
12 (9-15)%
17 (14-20)%
21 (17-25)%
23 (19-26)%

76 (70-81)%
63 (57-70)%
51 (44-58)%
40 (34-47)%
38 (32-45)%
218

91 (89-93)%
83 (80-85)%
70 (67-73)%
60 (56-63)%
54 (51-57)%

13 (10-16)%
21 (17-24)%
28 (25-32)%
34 (30-38)%
35 (31-39)%

14 (9-18)%
19 (14-25)%
25 (20-31)%
29 (23-36)%
32 (26-38)%

2006-2012
Probability (95%CI)

904
86 (83-89)%
76 (72-79)%
63 (59-67)%
52 (48-57)%
47 (42-51)%

11 (7-15)%
17 (13-23)%
24 (18-30)%
30 (24-37)%
30 (24-37)%
214

N. evaluated

82 (79-84)%
71 (68-74)%
60 (57-63)%
51 (47-54)%
45 (42-49)%
892

29 (25-33)%
47 (42-51)%
58 (54-63)%
61 (57-65)%
62 (57-66)%

22 (19-24)%
41 (38-44)%
57 (54-60)%
61 (58-64)%
62 (58-65)%

P-value
0.02
0.02
<0.001
<0.001
<0.001
<0.001
0.24
0.48
0.27
0.34
0.63
0.41
0.02
<0.001
<0.001
<0.001
0.001
0.003
0.38
0.14
0.10
0.02
0.01
0.16
0.44
0.001
0.11
0.68
0.42
0.39

continued on the next page
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reduction in TRM for those with overall maximal grade
III-IV acute GvHD over time, relapse incidence increased.

Prognostic factors
Two major multivariate modeling approaches were
implemented to examine the effect of time period on OS
and TRM following the diagnosis of acute GvHD. First,
the effect of time period on outcome among cases of
grade II-IV acute GvHD was examined separately for the
tacrolimus-based GvHD prophylaxis group and
cyclosporine-based prophylaxis group (Table 4). Reasons
for this analysis include a recent trend to use tacrolimus
rather than cyclosporine-based acute GvHD prophylaxis.
These analyses demonstrated a significant improvement
in OS and reduction in TRM with more recent HCT
recipients among those who received tacrolimus-based
GvHD prophylaxis. In contrast, these effects were not
observed among those who received cyclosporine-based
GvHD prophylaxis. These conclusions remained in secondary analyses that: (i) re-categorized time period
cohorts (1999-2003, 2004-2008, 2009-2012), and (ii)
excluded patients with upper gastrointestinal tract acute
GvHD.
Given the significant impact of overall acute GvHD
grade on OS and TRM, a second modeling approach sep-

arately examined outcomes for the subgroups with either
overall grade II or grade III-IV acute GvHD (Table 4).
Similar reductions in hazards for OS and TRM were
observed for the tacrolimus-based prophylaxis group in
both overall grade II and grade III-IV acute GvHD, however these effects were only significant in the overall
grade II group. Adjusted OS and TRM plots for the
cyclosporine- and tacrolimus-based GvHD prophylaxis
groups separately are presented in Figure 1.

Discussion
This analysis provides new insight into trends in acute
GvHD severity over time and determinants of mortality
after the diagnosis of acute GvHD, and clarifies the relative impact of advances in GvHD outcomes according to
overall acute GvHD grade and GvHD prophylaxis groups.
We report several key findings. These data demonstrate a
shift in maximal grade of acute GvHD over time, such
that the relative contribution of grade III-IV disease
among those affected by acute GvHD in the period of
2006-2012 is 20% lower than that in 1999-2001 and 10%
lower than that in 2002-2005. This reduction in grade IIIIV disease is associated with a marked shift in GvHD pro-

continued from the previous page

Acute GvHD grade III-IV
Overall survival
100-day
6-month
1-year
2-year
3-year
Relapse
100-day
6-month
1-year
2-year
3-year
Transplant-related mortality
100-day
6-month
1-year
2-year
3-year
Disease-free survival
100-day
6-month
1-year
2-year
3-year
Chronic GvHD
100-day
6-month
1-year
2-year
3-year

278

455
55 (49-60)%
36 (31-42)%
27 (22-32)%
21 (16-26)%
19 (15-24)%

277

542
54 (49-58)%
42 (37-46)%
32 (28-36)%
25 (21-29)%
22 (19-26)%

449
9 (6-12)%
13 (9-17)%
14 (10-18)%
16 (12-20)%
16 (12-21)%

277

531
11 (8-14)%
15 (12-19)%
18 (15-22)%
21 (17-24)%
21 (18-25)%

449
43 (37-48)%
55 (49-61)%
61 (55-67)%
64 (59-70)%
65 (60-71)%

277

531

449

29 (25-33)%
35 (31-39)%
41 (37-45)%
45 (41-49)%
47 (43-51)%
531

47 (42-51)%
36 (32-41)%
28 (24-32)%
22 (19-26)%
20 (17-24)%
451

16 (12-21)%
29 (24-35)%
33 (27-38)%
34 (29-40)%
NE*

15 (12-19)%
20 (17-24)%
25 (21-29)%
28 (24-32)%
29 (25-33)%

43 (38-47)%
49 (44-53)%
54 (49-59)%
57 (53-62)%
58 (54-63)%

49 (43-55)%
32 (27-38)%
25 (20-30)%
20 (15-25)%
18 (14-23)%
276

65 (61-69)%
52 (48-56)%
40 (36-44)%
31 (27-35)%
26 (23-30)%

56 (52-60)%
45 (40-49)%
34 (30-38)%
27 (23-31)%
24 (21-28)%
532

14 (11-17)%
24 (20-28)%
32 (28-36)%
33 (29-38)%
33 (29-38)%

16 (13-19)%
27 (23-31)%
37 (33-41)%
40 (36-44)%
40 (36-44)%

0.001
<0.001
<0.001
<0.001
0.004
0.06
<0.001
0.009
0.02
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.010
0.01
<0.001
0.01
0.06
0.12
0.09
0.62
0.23
0.22
0.07
0.07

*:fewer than 15 patients eligible to be evaluated for chronic GvHD at 3 years after transplantation.
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phylaxis delivered over time, with tacrolimus-based
approaches comprising 80% of cases in the period 20062012. With that, mortality has decreased over time, and
deaths from organ failure and infection have decreased.
These data provide current benchmarks for further analyses and counseling of patients for expected current HCT
outcomes using these approaches.
Multivariate analyses demonstrated significant
improvements in OS and TRM over time but, importantly, refined these conclusions further. The effects appear
to be limited to those treated with tacrolimus-based
GvHD prophylaxis, and most apparent in those with
overall grade II acute GvHD. Given these findings, we
further examined GvHD characteristics, GvHD therapy,
and causes of death among the cyclosporine and
tacrolimus groups restricted to overall grade II disease
(Online Supplementary Tables S1 and S2). Among grade II
cases, the cyclosporine group had greater and more persistent representation of three-organ involvement
(skin+liver+gastrointestinal) across the time period
cohorts compared to the tacrolimus group. This GvHD

Table 3. Causes of death.
Number of deaths (%)
Primary disease
New malignancy
GvHD
Idiopathic pneumonia
Infection
Organ failure
Hemorrhage
Vascular
Othera
Missing

1999-2001

2002-2005

2006-2012

381
115 (30)
6 (2)
62 (16)
29 (8)
78 (20)
57 (15)
15 (4)
2 (<1)
7 (2)
10 (3)

690
234 (34)
10 (1)
148 (21)
48 (7)
104 (15)
95 (14)
8 (1)
4 (<1)
15 (2)
24 (3)

890
370 (42)
6 (<1)
183 (21)
27 (3)
137 (15)
108 (12)
6 (<1)
4 (<1)
16 (2)
33 (4)

a
Graft rejection (n=6), other HCT-related cause (n=5), accidental death (n=4), prior
malignancy (n=4), seizure (n=3), cerebral edema (n=2), diffuse alveolar damage
(n=2), drug overdose (n=2), acute myocardial infarction/myocardial infarction (n=2),
encephalopathy (n=1), bone marrow myelofibrosis and necrosis (n=1), hypovolemic
shock (n=1), leukoencephalopathy (n=1), numerous transient ischemic attacks (n=1),
post-transplant lymphoproliferative disease (n=1), Stevens-Johnson syndrome (n=1),
thrombotic thrombocytopenic purpura (n=1).

Table 4. Multivariate analysis results: effect of time cohort on overall survival and transplant-related mortality.

Overall survival
Cyclosporine A

HR

CI

1

Year of transplant
1999-2001
2002-2005
2006-2012

Tacrolimus

1.00
1.02

0.82-1.21
0.80-1.29

0.98
1.00
0.99
0.88

HR

CI

P-value

3

Year of transplant
1999-2001
2002-2005
2006-2012

0.0028
1.00
1.01
0.80

0.80-1.29
0.63-1.01

Transplant-related mortality
HR
CI

P-value

0.91
0.06

2

Year of transplant
1999-2001
2002-2005
2006-2012

0.97
1.00
1.00
0.97

0.81-1.24
0.75-1.26

0.99
0.83

HR

CI

P-value

4

Year of transplant
1999-2001
2002-2005
2006-2012

P-value

0.0079
1.00
0.83
0.66

0.61-1.12
0.49-0.90

0.22
0.007

Acute GvHD grade II

Overall survival
Tacrolimus

HR

CI

5

Year of transplant
1999-2001
2002-2005
2006-2012
Acute GvHD grade III-IV

1.00
1.02
0.80

0.0494

Tacrolimus

HR

0.69-1.51
0.55-1.16

Transplant-related mortality
HR
CI

P-value

0.91
0.25

6

Year of transplant
1999-2001
2002-2005
2006-2012

Overall survival
CI

5

Year of transplant
1999-2001
2002-2005
2006-2012

0.19
1.00
0.98
0.82

0.71-1.37
0.59-1.14

0.92
0.24

0.0397
1.00
0.60
0.51

0.34-1.04
0.30-0.87

Transplant-related mortality
HR
CI

P-value
6

Year of transplant
1999-2001
2002-2005
2006-2012

P-value

0.071
0.013

P-Value
0.0785

1.00
0.90
0.70

0.62-1.30
0.48-1.03

0.56
0.07

1
Significant factors (P<0.01) in the overall survival model among cyclosporine A recipients: acute GvHD grade (II vs. III-IV; P<0.0001),acute GvHD-affected organs (P<0.0001),
acute GvHD treatment (P=0.0001), disease status (P<0.0001), Karnofsky performance score (P=0.0014). Model stratified by disease, sex match, graft type. 2Significant factors in the
transplant-related mortality model among cyclosporine A recipients: acute GvHD grade (II vs. III-IV; P<0.0001), age (P=0.0016), acute GvHD-affected organs (P<0.0001), acute
GvHD treatment (P=0.0001), Karnofsky performance score (P=0.0020). Model stratified by sex match, graft type. 3Significant factors in the overall survival model among tacrolimus
recipients: acute GvHD grade (II vs. III-IV; P<0.0001), age (P<0.0001), acute GvHD-affected organs (P<0.0001), acute GvHD treatment (P=0.0001), disease status (P<0.0001), donor
type & age (P=0.0002), Karnofsky performance score (P=0.0003). Model stratified by disease, sex match, graft type. 4Significant factors in the transplant-related mortality model
among tacrolimus recipients: acute GvHD grade (II vs. III-IV; P<0.0001), age (P=0.0007), acute GvHD-affected organs (P<0.0001), acute GvHD treatment (P=0.0001), donor type &
age (P<0.0001). Model stratified by sex match, graft type. 5Overall survival models for tacrolimus recipients stratified by disease, sex match, graft type. 6The transplant-related mortality models for tacrolimus recipients were stratified by sex match, graft type.

964

haematologica | 2017; 102(5)

Outcomes of acute GvHD over time

phenotype (skin+liver+gastrointestinal) was associated
with greater mortality on multivariate analysis.
Additionally, re-categorization of the acute GvHD subjects in the cyclosporine and tacrolimus groups according
to the refined Minnesota risk classification demonstrated
that a greater and relatively fixed proportion of overall
grade II acute GvHD subjects in the cyclosporine group
had high-risk disease over the respective time period
cohorts (Online Supplementary Table S3).13 High-risk
patients by this classification have been shown to have
inferior treatment response and increased TRM.13,14
Otherwise, we found no major differences in acute
GvHD therapy between the cyclosporine and
tacrolimus-based prophylaxis groups to explain differential survival outcome. Analysis of cause of death information suggested a decrease in deaths related to infections and organ failure in the tacrolimus group, but not in
the cyclosporine group. We acknowledge that prior
major randomized trials examining tacrolimus versus
cyclosporine (both in combination with methotrexate)

have demonstrated no major difference in survival outcome.2,3 This current retrospective analysis differs in that
it is exclusively focused on survival estimation from time
of acute GvHD onset among those with acute GvHD,
and includes patients transplanted in the decade following these major trials.
While these effects were most apparent in overall grade II
acute GvHD, we note that similar effects were seen in the
grade III-IV GvHD group that had received tacrolimusbased prophylaxis. These findings are further supported by
a recent analysis that examined mortality after grade III-IV
acute GvHD among 427 patients, in whom significant
improvements in OS and TRM were observed in the comparison of a 2007-2012 group versus a 1997-2006 group.15
These findings were predominantly identified in the grade
IV acute GvHD subgroup in this analysis. While important
differences between the two study populations limit direct
comparison, these findings support the concept that HCT
outcome has improved for patients with grade III-IV acute
GvHD also in the current era.

B

A

Figure 1. The adjusted probability of overall survival following a diagnosis of grade
II-IV acute graft-versus-host
disease. Patients treated
with tacrolimus-based GVHD
prophylaxis are detailed in (A)
and those with cyclosporinebased GVHD prophylaxis are
detailed in (B).

B

A

Figure 2. The adjusted probability of transplant-related
mortality following a diagnosis of grade II-IV acute graftversus-host disease. Patients
treated with tacrolimus-based
GVHD prophylaxis are detailed
in (A) and those with
cyclosporine-based GVHD prophylaxis are detailed in (B).
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We note the following limitations to this analysis. First,
we conducted analyses based on the reported maximal
acute GvHD severity, but survival estimation was done
from the time of the onset of the acute GvHD. Next, limitations in data on cyclosporine and tacrolimus therapeutic
drug levels, prednisone dose information, and type/extent
of second-line therapy make detailed analyses of treatment
intensity on outcome not possible. Additionally, detailed
acute GvHD treatment response data are not available, so
we cannot characterize the burden of steroid-refractory
disease across groups. Furthermore, based on the stated
inclusion criteria for the analysis, these findings cannot be
extended to recipients of reduced intensity conditioning.
Finally, insufficient data on antimicrobial agents limit
analysis of changes in these practices over time as a potential determinant of improved outcome. In conclusion, this
analysis has shown that survival has improved over time in
tacrolimus-based acute GvHD prophylaxis HCT recipients
who develop acute GvHD.
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